Skip to main content
Science / Explained
Inside the Peptide MarketArticle 3 of 5

How Shortages Change Access Overnight

Shortage-based compounding access is a temporary condition tied to supply pressure — when that pressure lifts, the access structure can change with it.

How Shortages Change Access Overnight
Shortage-based compounding access is a temporary condition tied to supply pressure — when that pressure lifts, the access structure can change with it.

Access can feel stable until it is not. For a period of time, a product may be available, pricing may feel predictable, and the process may become familiar. People start to believe the path they are using will remain open because it has been open for months. Then the market changes.

The compound has not changed. The science has not changed. But the access point changes.

That is what makes shortages so disruptive.

THE ACCESS WINDOW

Shortages can temporarily reshape the market. When an FDA-approved drug is listed as being in shortage, certain compounding pathways may become available under specific legal conditions. This does not mean the compounded version has been FDA-approved. It means the shortage creates a temporary environment where certain forms of compounding may be permitted if the compounder meets applicable requirements.

That distinction matters.

The access exists because the system is under pressure. When the shortage changes, the access structure can change with it.

THE SHIFT

This is why access can feel like it changes overnight. During a shortage, more sources may appear. More pricing options may exist. The market may feel more flexible. People may assume that flexibility is permanent because it becomes part of their routine.

But shortage-based access is not designed to be permanent.

When supply stabilizes and the FDA determines that a shortage has been resolved, compounders may be required to stop making products that are essentially copies of FDA-approved drugs, subject to specific rules and enforcement timelines. In the semaglutide shortage resolution, the FDA described additional periods of enforcement discretion of 60 days for certain 503A compounders and 90 days for 503B outsourcing facilities.

From the outside, that can feel sudden. A source that was available one month may no longer be available the next. Prices can shift as options contract. People who built their routine around one access pathway may have to start evaluating alternatives.

THE CONFUSION

The confusing part is that the molecule remains recognizable while the system around it changes. This is where many people feel caught off guard. They are not reacting to a change in the science. They are reacting to a change in the legal, supply, and distribution environment around that science.

That is why access is not just a product issue. It is a system issue.

The same compound can move through different access pathways depending on shortage status, regulatory position, supply conditions, and distribution model. When any of those variables change, the person at the end of the chain feels the impact.

What this means

Shortages teach one important lesson: access is not guaranteed just because demand exists.

A source may be available because of a temporary condition. A price may exist because of a temporary market structure. A familiar pathway may depend on rules that can change once supply stabilizes.

The useful question is not only: can I access this today? The better question is: what system is making this access possible, and how stable is that system?

In this market, the compound may remain the same while the door to access changes. That is why understanding the system matters.

In this market, the compound may remain the same while the door to access changes.

Previous
What "Same Compound" Actually Means Across Sources
Next
Why Telehealth Models Collapse
Related articles

Why Telehealth Models Collapse

Telehealth reduced friction and made GLP-1 access feel modern — but models built for rapid expansion become exposed when pricing, supply, and regulatory conditions change.

Why Telehealth Models Collapse

Why Prices Vary So Much in Peptides

Peptide prices look irrational until you see what each price actually includes — synthesis, purity, testing, documentation, and the layers between production and you.

Why Prices Vary So Much in Peptides
References4 sources
  1. U.S. Food and Drug Administration · 2025
    Declaratory Order: Resolution of Shortages of Semaglutide Injection Products.
    U.S. Food and Drug Administration
  2. U.S. Food and Drug Administration · 2024
    FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize.
    U.S. Food and Drug Administration
  3. Reuters · 2024
    FDA clarifies policies on compounding of GLP-1 medicines.
    Reuters
  4. Advisory Board · 2025
    Companies find ways around end of GLP-1 shortage.
    Advisory Board